Terms: = Gastric cancer AND HOXD13, SPD, 3239, P35453, HOX4I
31 results:
1. Phase I/II clinical trial of efficacy and safety of EGCG oxygen nebulization inhalation in the treatment of COVID-19 pneumonia patients with cancer.
Yin X; Zhu W; Tang X; Yang G; Zhao X; Zhao K; Jiang L; Li X; Zhao H; Wang X; Yan Y; Xing L; Yu J; Meng X; Zhao H
BMC Cancer; 2024 Apr; 24(1):486. PubMed ID: 38632501
[TBL] [Abstract] [Full Text] [Related]
2. The combination of soluble forms of PD-1 and PD-L1 as a predictive marker of PD-1 blockade in patients with advanced cancers: a multicenter retrospective study.
Kurosaki T; Chamoto K; Suzuki S; Kanemura H; Mitani S; Tanaka K; Kawakami H; Kishimoto Y; Haku Y; Ito K; Sato T; Suminaka C; Yamaki M; Chiba Y; Yaguchi T; Omori K; Kobayashi T; Nakagawa K; Honjo T; Hayashi H
Front Immunol; 2023; 14():1325462. PubMed ID: 38149256
[TBL] [Abstract] [Full Text] [Related]
3. Soluble PD-L1 as a diagnostic and prognostic biomarker in resectable gastric cancer patients.
Chivu-Economescu M; Herlea V; Dima S; Sorop A; Pechianu C; Procop A; Kitahara S; Necula L; Matei L; Dragu D; Neagu AI; Bleotu C; Diaconu CC; Popescu I; Duda DG
Gastric Cancer; 2023 Nov; 26(6):934-946. PubMed ID: 37668884
[TBL] [Abstract] [Full Text] [Related]
4. Prognostic value of soluble PD-L1 and exosomal PD-L1 in advanced gastric cancer patients receiving systemic chemotherapy.
Shin K; Kim J; Park SJ; Lee MA; Park JM; Choi MG; Kang D; Song KY; Lee HH; Seo HS; Lee SH; Kim B; Kim O; Park J; Kang N; Kim IH
Sci Rep; 2023 Apr; 13(1):6952. PubMed ID: 37117200
[TBL] [Abstract] [Full Text] [Related]
5. Soluble Programmed Cell Death Ligand-1 (spd-L1) Levels in Various cancer Types and Normal Populations.
Lee SH; Park HJ; Moon JY; Kim YT; Lee KR; Kwak MJ; Kim YJ
Clin Lab; 2023 Apr; 69(4):. PubMed ID: 37057933
[TBL] [Abstract] [Full Text] [Related]
6. Soluble programmed cell death ligand 1 predicts prognosis for gastric cancer patients treated with nivolumab: Blood-based biomarker analysis for the DELIVER trial.
Kawakami H; Sunakawa Y; Inoue E; Matoba R; Noda K; Sato T; Suminaka C; Yamaki M; Sakamoto Y; Kawabata R; Ishiguro A; Akamaru Y; Kito Y; Yabusaki H; Matsuyama J; Takahashi M; Makiyama A; Hayashi H; Chamoto K; Honjo T; Nakagawa K; Ichikawa W; Fujii M
Eur J Cancer; 2023 May; 184():10-20. PubMed ID: 36889037
[TBL] [Abstract] [Full Text] [Related]
7. Unbalanced expression of sICOS and spd-1 correlates with tumor progression in gastric cancer.
Lima CAC; da Silva LM; Dos Santos RL; Silva JPA; Forones NM; Martins MR; Torres LC
J Surg Oncol; 2022 Jul; 126(1):144-149. PubMed ID: 35689579
[TBL] [Abstract] [Full Text] [Related]
8. Circulating PD-L1 is associated with T cell infiltration and predicts prognosis in patients with CRLM following hepatic resection.
Chen X; Du Z; Huang M; Wang D; Fong WP; Liang J; Fan L; Wang Y; Yang H; Chen Z; Hu M; Xu R; Li Y
Cancer Immunol Immunother; 2022 Mar; 71(3):661-674. PubMed ID: 34322779
[TBL] [Abstract] [Full Text] [Related]
9. Prognostic significance of soluble forms of immune checkpoint PD-1/PDL1 receptor and ligand in blood plasma of gastric cancer patients.
Kushlinskii NE; Gershtein ES; Chang VL; Korotkova EA; Alferov AA; Kontorshchikov MM; Sokolov NY; Karamysheva EI; Ognerubov NA; Stilidi IS
Klin Lab Diagn; 2021 Mar; 66(3):139-146. PubMed ID: 33793112
[TBL] [Abstract] [Full Text] [Related]
10. GALNT10 promotes the proliferation and metastatic ability of gastric cancer and reduces 5-fluorouracil sensitivity by activating hoxd13.
Xu G; Wu YL; Li N; Xu R; Zhang JB; Ming H; Zhang Y
Eur Rev Med Pharmacol Sci; 2020 Nov; 24(22):11610-11619. PubMed ID: 33275228
[TBL] [Abstract] [Full Text] [Related]
11. [The content of the soluble forms PD-1 and PD-L1 in blood serum of patients with gastric cancer and their relationship with clinical and morphological characteristics of the disease.].
Gershtein ES; Ognerubov NA; Chang VL; Delektorskaya VV; Korotkova EA; Sokolov NY; Polikarpova SB; Stilidi IS; Kushlinskii NE
Klin Lab Diagn; 2020; 65(6):347-352. PubMed ID: 32459892
[TBL] [Abstract] [Full Text] [Related]
12. Clinicopathological Features, Treatment Strategy, and Prognosis of Primary Non-Hodgkin's Lymphoma of the Duodenum: A SEER Database Analysis.
Zheng G; Wang Y; Zhao Y; Zheng Z
Can J Gastroenterol Hepatol; 2020; 2020():9327868. PubMed ID: 32399459
[TBL] [Abstract] [Full Text] [Related]
13. Multicenter phase II study of SOX plus trastuzumab for patients with HER2
Yuki S; Shinozaki K; Kashiwada T; Kusumoto T; Iwatsuki M; Satake H; Kobayashi K; Esaki T; Nakashima Y; Kawanaka H; Emi Y; Komatsu Y; Shimokawa M; Makiyama A; Saeki H; Oki E; Baba H; Mori M
Cancer Chemother Pharmacol; 2020 Jan; 85(1):217-223. PubMed ID: 31768696
[TBL] [Abstract] [Full Text] [Related]
14. Comparison of bowel-cleansing efficacy of split-dose and same-day dose bowel preparation for afternoon colonoscopy in patients with gastrectomy: a prospective randomized study.
Gweon TG; Huh CW; Ji JS; Kim CH; Kim JJ; Park SM
Surg Endosc; 2020 Oct; 34(10):4413-4421. PubMed ID: 31624941
[TBL] [Abstract] [Full Text] [Related]
15. Plasma Levels of Soluble PD-L1 Correlate With Tumor Regression in Patients With Lung and gastric cancer Treated With Immune Checkpoint Inhibitors.
Ando K; Hamada K; Watanabe M; Ohkuma R; Shida M; Onoue R; Kubota Y; Matsui H; Ishiguro T; Hirasawa Y; Ariizumi H; Tsurutani J; Yoshimura K; Tsunoda T; Kobayashi S; Wada S
Anticancer Res; 2019 Sep; 39(9):5195-5201. PubMed ID: 31519633
[TBL] [Abstract] [Full Text] [Related]
16. Soluble PD-L1 Expression in Circulation as a Predictive Marker for Recurrence and Prognosis in gastric cancer: Direct Comparison of the Clinical Burden Between Tissue and Serum PD-L1 Expression.
Shigemori T; Toiyama Y; Okugawa Y; Yamamoto A; Yin C; Narumi A; Ichikawa T; Ide S; Shimura T; Fujikawa H; Yasuda H; Hiro J; Yoshiyama S; Ohi M; Araki T; Kusunoki M
Ann Surg Oncol; 2019 Mar; 26(3):876-883. PubMed ID: 30565045
[TBL] [Abstract] [Full Text] [Related]
17. Pathological Significance and Prognostic Value of Surfactant Protein D in cancer.
Mangogna A; Belmonte B; Agostinis C; Ricci G; Gulino A; Ferrara I; Zanconati F; Tripodo C; Romano F; Kishore U; Bulla R
Front Immunol; 2018; 9():1748. PubMed ID: 30127783
[TBL] [Abstract] [Full Text] [Related]
18. Microsatellite Instability and Programmed Cell Death-Ligand 1 Expression in Stage II/III gastric cancer: Post Hoc Analysis of the CLASSIC Randomized Controlled study.
Choi YY; Kim H; Shin SJ; Kim HY; Lee J; Yang HK; Kim WH; Kim YW; Kook MC; Park YK; Kim HH; Lee HS; Lee KH; Gu MJ; Choi SH; Hong S; Kim JW; Hyung WJ; Noh SH; Cheong JH
Ann Surg; 2019 Aug; 270(2):309-316. PubMed ID: 29727332
[TBL] [Abstract] [Full Text] [Related]
19. [Analysis on the clinical therapeutic effects of arterial first approach pancreatoduodenectomy in the treatment of borderline resectable pancreatic adenocarcinoma].
Jin G; Zheng KL; Guo SW; Shao Z; Liu C; Shi XH; Liu RD; Bai SJ; Jiang H; Bian Y; Hu XG
Zhonghua Wai Ke Za Zhi; 2017 Dec; 55(12):909-915. PubMed ID: 29224265
[No Abstract] [Full Text] [Related]
20. Association between serious psychological distress and nonparticipation in cancer screening and the modifying effect of socioeconomic status: Analysis of anonymized data from a national cross-sectional survey in Japan.
Fujiwara M; Inagaki M; Nakaya N; Fujimori M; Higuchi Y; Kakeda K; Uchitomi Y; Yamada N
Cancer; 2018 Feb; 124(3):555-562. PubMed ID: 29076156
[TBL] [Abstract] [Full Text] [Related]
[Next]
